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Abstract
Electrochemotherapy (ECT) is a novel anticancer therapy that is currently being evaluated in human
and pet cancer patients. ECT associates the administration of an anti-tumor agent to the delivery
of trains of appropriate waveforms. The increased uptake of chemotherapy leads to apoptotic
death of the neoplasm thus resulting in prolonged local control and extended survival. In this paper
we describe the histological features of a broad array of spontaneous tumors of companion animals
receiving pulse-mediated chemotherapy. Multivariate statistical analysis of the percentage of
necrosis and apoptosis in the tumors before and after ECT treatment, shows that only a high
percentage of necrosis and apoptosis after the ECT treatment were significantly correlated with
longer survivals of the patients (p < 0.0001 and p = 0.004, respectively). Further studies on this
topic are warranted in companion animals with spontaneous tumors to identify new molecular
targets for electrochemotherapy and to the develop new therapeutical protocols to be translated
to humans.
Background
Local management of solid neoplasms in humans gener-
ally involves multimodality approaches whose corner-
stones are surgery combined with radiation therapy [1,2].
The usual radiation protocols are based on preoperative,
intra-operative, or post-operative external beam treatment
or adjuvant brachytherapy [3]. The aim of these strategies
is to optimize local control while minimizing side effects,
especially in the case of limb neoplasms. For these reasons
low dose external beam fractionation is usually preferred,
however in case of large cancers that involve deep under-
lying structures, preoperative radiation therapy might be
chosen [4]. Unfortunately the rate of local wound compli-
cation associated with aggressive surgical management
and radiation therapy is still elevated [5]. Electrochemo-
therapy (ECT) is a new approach to solid tumors that
associates the administration of a chemotherapy agent to
the application of square or biphasic electric pulses (EP)
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so to increase the uptake of drug by the cancer cells [6,7].
This approach can lead to tumor destruction through
apoptotic death at least when using bleomycin as antican-
cer agent [8], resulting in tumor control or palliation with
minimal side effects. Over the past years our group
focused on the development of novel ECT protocols in
pets affected by advanced cancer as a model for down-
staged human patients. After preliminary studies involv-
ing also the development of custom-tailored electrodes
[9,10] we studied the impact of ECT on several cohorts of
canine and feline patients affected by spontaneously
occurring tumors [11-13].
The high rate of local control in our preliminary investiga-
tion [9] that accounted for an overall 80% response (40%
long lasting), prompted us to mount several phase II stud-
ies.
Many tumor histotypes show a marked responsiveness to
pulse-mediated chemotherapy, leading to tumor shrink-
age and clinical remission. In particular, ECT seems prom-
ising at controlling oral mucosal melanomas either as a
single modality therapy or in conjunction with surgical
cytoreduction [11]. Moreover, ECT can be employed not
only to directly attack neoplasms but can also be used in
an adjuvant fashion to treat residual disease, thus steriliz-
ing the surgical field in case of incomplete excision as per
radiation therapy [11-13]. Of interest, tumors reported to
be resistant to this clinical strategy [14] became highly
responsive when it has been coupled with surgery as evi-
denced by a recent publication [12].
Despite the consistent number of preclinical and clinical
publications on this topic, there are few data on the his-
topathological modifications induced by this therapy
[15]. Mir and coll. described massive necrosis induced by
ECT in cats harboring post-vaccinal sarcomas, character-
ized by diffuse infiltration of the tumor perimeter by mac-
rophages, lymphocytes and eosinophils [14].
The lack of extensive investigation in this field prompted
us to run a thorough revision of our histological samples
to gather a broader picture of patterns of tumor response
and eventually to identify possible prognostic factors.
Methods
Electrochemotherapy protocol
A total of 127 companion animals with spontaneous
tumors were enrolled in different phase II ECT trials over
a 7 years period and biopsies were collected at presenta-
tion, after the first session of ECT and at the completion of
the treatment (Table 1). Pets that entered in our studies
received two sessions of ECT one week apart (two weeks
for patients with cardiomyopathy) under sedation with
medetodimine and ketamine as per manufacturer's
instruction. Briefly the tumor's bed and the margins for 1/
2 cm in all directions were infiltrated with bleomycin at
the concentration of 1.5 mg/ml. Five minutes after the
infiltration, trains of 8 biphasic electric pulses lasting 50 +
50 µs each, with 1 ms interpulse intervals, were delivered
by means of modified caliper electrodes [10]. In figure 1
is shown the appearance of one of such pulses; a more
thorough technical description has already been else-
where published [7].
Morphological analyses
Biopsies (surgical and punch samplings) were collected
before the beginning of ECT, after one session (one week
after the treatment) and at the completion of the protocol
(two weeks after the end of the protocol). More than 370
specimens were analyzed. Histopathology specimens
embedded in paraffin have been cut into 6 µm sections
and stained following standard protocols, using Hema-
toxylin/Eosin, Hematoxylin/Van Gieson, and toluidine
blue staining (to identify poorly differentiated mast cell
A biphasic waveform adopted for ECT Figure 1
A biphasic waveform adopted for ECT. A diagram 
showing the electrical features of a biphasic electric pulse 
generated by a CHEMOPULSE.
Table 1: Tumor types treated with ECT in 127 companion 
animals with spontaneously occurring neoplasms
Tumor type Species Number of patients
Oral melanoma Dog 10
Soft tissue sarcoma Cat 19 + 39
Soft tissue sarcoma Dog 22
Mast cell tumor Dog 28
Squamous cell 
carcinoma
Cat 9Journal of Translational Medicine 2007, 5:48 http://www.translational-medicine.com/content/5/1/48
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tumors) [16]. The TUNEL reaction was performed using
the peroxidase-based Apoptag kit (Oncor, Gaithersburg,
MD), as previously described [17]. In order to confirm the
diagnoses, histological examination of the biopsies were
independently performed by two pathologists (FB and
AB) that were not informed of the clinical outcome of the
veterinary patients that were staged, treated and followed
up by another investigator (EPS).
Statistical analysis
Histopathological patterns were tested for significance
regarding response to first treatment, response to second
session of ECT and the recurrence within the first six
months of follow-up. Patients died of unrelated disease
were censored in the analysis. Variables tested were: per-
centage of necrosis, apoptotic index. All analyses were per-
formed following an intention to treat analysis method.
The time to progression was calculated as the period from
the date of starting treatment to the first observation of
disease progression or to death from any cause. Survival
plot were performed by Kaplan-Meier product-limit
method [18]. The differences in terms of survival accord-
ing to the degree of apoptosis and necrosis (both pre- and
post-treatment) were evaluated by the log-rank test [19].
Finally, the Cox proportional hazards model was applied
to the multivariate survival analysis [20]. SPSS software
(version 11.05, SPSS, Chicago) was used for statistical
analysis. A P value of less than 0.05 was considered to
indicate statistical significance.
Results
The review of more than 370 bioptic specimens allowed
to determine different features of tumor histopathology
following ECT. Patterns of response in the early phases of
the treatment (after 1 session of ECT) involved an acute
inflammatory response made up of neutrophils, lym-
phocytes and plasmacells, followed by extensive necrosis.
At the completion of the treatment (after two weeks), the
tumor samples showed a dramatic decrease in cell
number, with the majority of the remaining cells in apop-
tosis with no inflammatory response, while most of the
residual tumor mass was made up of scar tissue. In three
cases of feline sarcomas that experienced local failure, the
tumor recurred as a less aggressive histotype: a neurofi-
broma-like lesion rather than an high grade sarcoma.
Interestingly, we always detected lack of sufferance in the
normal tissues surrounding the neoplasm. Table 2 sum-
marizes the histopathological features of the ECT-treated
cancers, that have been encountered in this study. In fig-
ure 2 several examples of the histopathological appear-
ance of different tumors, are depicted (see the figure
legend for the details). When we statistically analyzed the
percentage of necrosis and apoptosis in the tumors before
and after the first ECT treatment, we found that high per-
centage of necrosis after the ECT treatment was signifi-
cantly correlated with survival (p < 0.0001), while the
extent of necrosis in the untreated tumors did not corre-
late with survival (p = 0.427). On the other hand an high
apoptotic rate of both untreated tumors and tumor ana-
lyzed after the first ECT treatment significantly correlated
with survival (p < 0.0001). In figure 3 the corresponding
Kaplan-Meier curves are depicted. Interestingly, when we
performed multivariate analysis on the same histopatho-
logical parameters, we found that only high levels of
necrosis and apoptosis after the ECT treatment signifi-
cantly correlated with a better longer survival of the
patients (Table 3).
Discussion
ECT has several advantages on other anti-tumor tech-
niques: ease of administration, low cost, minimal toxicity
(usually limited to mild focal inflammation at the treated
site), and high response rate. Our morphological study
shows on a broad selection of tumors of companion ani-
mals a progressive and highly selective destruction that
frequently allowed conservative surgeries in the case of
extensive tumors. The histopathological analysis of the
treated tumor revealed that cancer cells did not undergo
the typical response to bleomycin consisting with enlarge-
ment and polynucleation [8], but evidenced marked
necrosis circumscribed to the tumour tissue, and an asso-
ciated acute inflammatory response mediated by lym-
phocytes and plasma cells. In the second phase of the
treatment, neoplastic apoptotic cells are detected in most
of the tumour mass, with no signs of acute inflammation.
This apoptotic pattern could be a consequence not only of
the ECT but also a phenomenon mediated by cellular
Table 3: Correlation with survival in multivariate analysis of the 
histopathological parameters selected
Risk factor Relative risk (95% C.I.) P value
Necrosis post > 55 0.066 (0.024 – 0.179) <0.0001
Necrosis post ≤ 55 1
Apoptosis pre > 3 0.534 (0.267 – 1.072) 0.078
Apoptosis pre ≤ 31
Apoptosis post > 9 0.352 (0.173 – 0.715) 0.004
Apoptosis post ≤ 91
Pre = before ECT treatment; Post = after the first ECT treatment
Table 2: Main histopathological features of the ECT-treated 
cancers
Phase of treatment* Histopathological pattern
Early phase (First 
session of ECT)
acute inflammatory response followed by 
necrosis and apoptosis
End of treatment 
(second session of 
ECT)
no inflammatory response, necrosis, scar 
tissue and apoptosis of the residual tumor 
cells
* See the text for the detailed description of the treatmentJournal of Translational Medicine 2007, 5:48 http://www.translational-medicine.com/content/5/1/48
Page 4 of 6
(page number not for citation purposes)
Histopathological patterns of tumor responses to ECT treatment Figure 2
Histopathological patterns of tumor responses to ECT treatment. A) A high grade feline fibrosarcoma situated 
between the scapulae of a cat before the ECT treatment (Haematoxylin and Eosin, original magnification × 20). B) The same 
lesion after completion of the ECT treatment (two weeks) is shown: note the almost complete disappearance of the neoplastic 
cells, substituted by scar tissue (Haematoxylin/Van Gieson, original magnification × 20). C) The recurrence as a neurofibroma-
like lesion at the site of a previously treated feline fibrosarcoma is depicted. The phenomenon in this particular patient 
occurred twelve months after the completion of the ECT course (Haematoxylin and Eosin, original magnification × 20). D) A 
canine cutaneous MCT before the ECT treatment (Haematoxylin and Eosin, original magnification × 20). E) The same lesion at 
the end of the adjuvant ECT treatment for incomplete surgical excision is shown: note the dramatic reduction in cellularity of 
the lesion (Haematoxylin and Eosin, original magnification × 20). F) An higher magnification of figure 1E, demonstrating that the 
most of the residual neoplastic cells are apoptotic (TUNEL reaction, original magnification × 40). G) A canine oral melanoma 
before ECT treatment (Haematoxylin and Eosin, original magnification × 20). H) A detail of figure 1G, showing the local aggres-
sivity of the neoplasm, that invades the muscular tissue (Haematoxylin and Eosin, original magnification × 40). I) The same 
tumor after completion of the ECT treatment (two weeks): most of the neoplastic cells are destroyed and substituted by scar 
tissue (Haematoxylin/Van Gieson, original magnification × 20). J) A cutaneous squamous cell carcinoma in a cat after the first 
ECT treatment: note the partial destruction of the neoplasm and the inflammatory process, consisting mainly of lymphocytes, 
neutrophils and plasma cells (Haematoxylin and Eosin, original magnification × 20). K) A very aggressive canine haemangiopery-
citoma before ECT treatment (Haematoxylin and Eosin, original magnification × 40). L) The same neoplasm after two ECT 
treatments: note the partial destruction of the tumor, substituted by scar tissue and the integrity of the normal skin, over the 
neoplasm (Haematoxylin and Eosin, original magnification × 20).Journal of Translational Medicine 2007, 5:48 http://www.translational-medicine.com/content/5/1/48
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immunity, depending on the presence of a mixed T and B
lymphocyte population (data not shown). When we sta-
tistically analysed the levels of necrosis and apoptosis in
the tumours before and after ECT treatment, we found
that either high necrosis and high apoptosis in the treated
tumours were correlated with an higher survival. As it was
logical to think, the percentage of necrosis in the
untreated tumours did not display any significant correla-
tion, while an high apoptotic rate in the untreated
tumours was, indeed, significantly correlated with sur-
vival. These data are in agreement with several observa-
tion that in several human and animal different tumour
histotypes, the apoptotic rate is an important prognostic
factor [21]. Nevertheless, when we performed a multivar-
iate analysis with the same histopathological parameters,
we found that only an high level of necrosis and apoptosis
after the ECT treatment, significantly correlated with a
longer survival. This result reinforces the idea that it is the
destruction of the tumours by the ECT treatment that is
responsible for the survival of the patients.
On the other hand, this pattern of tumor lysis seems to
play a key role in the prevention of local recurrence and
distant dissemination for melanomas treated with this
technique. In fact, we recently described a vitiligo-like
lesion in canine malignant melanomas of the oral cavity
where the absence of any pigment at the treatment site in
the long term survivors might imply the aiming of the
immune system to melanin and other deep melanoma
antigens [11]. Another pattern of response, at the moment
observed only in three cases of feline high grade sarcomas,
suggests that ECT seems to promote a selection of tumor
Kaplan-Meier survival plots for necrosis before ECT treatment (A); necrosis after the first ECT treatment (B); apoptosis before  ECT treatment (C); apoptosis after the first ECT treatment (D) Figure 3
Kaplan-Meier survival plots for necrosis before ECT treatment (A); necrosis after the first ECT treatment (B); apoptosis before 
ECT treatment (C); apoptosis after the first ECT treatment (D).Journal of Translational Medicine 2007, 5:48 http://www.translational-medicine.com/content/5/1/48
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cells, leading to a local recurrence in the form of a less
aggressive histotype: a neurofibroma-like lesion rather
than an high grade sarcoma.
To the best of our knowledge, this is the most extensive
description of histopathological patterns of response to
electrochemotherapy in tumors of companion animals,
showing previously undescribed mechanisms of response.
The morphological analysis further confirm the efficacy
and selectivity of this novel anticancer treatment as evi-
denced by the lack of sufferance elicited in the normal tis-
sues surrounding the neoplasms. Studies are currently
ongoing at our laboratory to further define the nature of
the immune response elicited by the ECT treatment, in
order to refine and ameliorate the efficacy of our proto-
cols.
Conclusion
Spontaneous tumors of pets share striking clinical, his-
topathological and molecular similarities with their
human counterparts, thus providing an invaluable bench
to clinic bridging [22].
The results of our studies are being currently translated to
humans [23]. Indeed, the data presented in this article,
combined with the preclinical results obtained in com-
panion animals will be instrumental to identify new
molecular targets and to plan more efficacious and less
invasive ECT protocols to be transferred to humans.
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